Pharma BD Deal Intelligence
A $5.3B all-cash acquisition ($24/share) that made Roche the world's fourth-largest pharmaceutical company. Syntex's Naprosyn and Synalar brands strengthened Roche's US presence in pain and dermatologic treatment, though the deal marked the last major move before Syntex's roster faded from Roche's portfolio.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
EU OKs Roche acquisition of Syntex, clearing a major regulatory hurdle for the $5.3 billion deal.
FTC consent order addressing antitrust concerns in Roche's $5.3 billion acquisition of Syntex Corporation, requiring certain divestitures to preserve…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Roche Holding acquired Syntex Corporation for $5.3 billion ($24/share in cash), making Roche the fourth-largest pharmaceutical company in the world. The deal strengthened Roche's US presence and added Syntex's anti-inflammatory and hormonal drug portfolio.
50M US cases/yr · $8.0B Global NSAID Market (1994)
Chronic pain and inflammatory joint disease (osteoarthritis, RA, musculoskeletal pain) affect tens of millions of US adults; rheumatoid arthritis alone is 2-3x more prevalent in women (NIAMS). NSAIDs such as naproxen inhibit COX-1/COX-2 to reduce prostaglandin-mediated pain, inflammation, and fever, and remain first-line for mild-to-moderate pain despite GI, renal, and cardiovascular risk considerations that shaped later COX-2-selective competition (Celebrex, rofecoxib).
Beyond the naproxen franchise, Roche valued Syntex's Palo Alto research campus and hormonal drug expertise (including Synalar for dermatologic conditions). The acquisition strengthened Roche's US commercial presence and made it the fourth-largest pharmaceutical company globally.
$24/share (57% premium). Would make Roche fourth-largest pharma globally. Part of Roche Holding AG's $5.3B deal to acquire Syntex Corporation.
European Commission cleared acquisition without conditions. Regulatory step in Roche Holding AG's acquisition process for Syntex Corporation.
Roche Holding AG completed its acquisition of Syntex Corporation for $5.3B. Roche Holding acquired Syntex Corporation for $5.3 billion ($24/share in cash), making Roche the fourth-largest pharmaceutical company in the world.
Roche created Roche Bioscience in Palo Alto from Syntex. Major workforce reductions.
Remaining Syntex facilities in Stanford Research Park closed after 14 years. Part of Roche Holding AG's $5.3B deal to acquire Syntex Corporation.
See timeline for full assessment. Assessment of Roche Holding AG's $5.3B acquisition of Syntex Corporation and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Syntex Corporation (this deal) | 1994 | $5.3B | 59 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 1994 deals · Roche Holding AG deals · Dermatology deals